ROIV Stock Overview
A commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas.
Snowflake Score | |
---|---|
Valuation | 6/6 |
Future Growth | 2/6 |
Past Performance | 3/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
Roivant Sciences Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$10.83 |
52 Week High | US$13.24 |
52 Week Low | US$8.25 |
Beta | 1.25 |
11 Month Change | -1.37% |
3 Month Change | -0.092% |
1 Year Change | 19.67% |
33 Year Change | 9.39% |
5 Year Change | n/a |
Change since IPO | 4.13% |
Recent News & Updates
Recent updates
Roivant Sciences: Executing On Huge Buyback Program With More To Come
Jun 02Roivant Sciences: $7bn Televant Sale Sets It Up For Long-Term Success
Mar 18We Believe Roivant Sciences' (NASDAQ:ROIV) Earnings Are A Poor Guide For Its Profitability
Feb 21These Analysts Just Made A Decent Downgrade To Their Roivant Sciences Ltd. (NASDAQ:ROIV) EPS Forecasts
Nov 15Are Investors Undervaluing Roivant Sciences Ltd. (NASDAQ:ROIV) By 21%?
Apr 26Broker Revenue Forecasts For Roivant Sciences Ltd. (NASDAQ:ROIV) Are Surging Higher
Nov 22Newsflash: Roivant Sciences Ltd. (NASDAQ:ROIV) Analysts Have Been Trimming Their Revenue Forecasts
Sep 29Roivant Sciences Ltd. (NASDAQ:ROIV) Analysts Are Reducing Their Forecasts For This Year
Aug 21Roivant Sciences GAAP EPS of -$0.48, revenue of $4.32M
Aug 15An Intrinsic Calculation For Roivant Sciences Ltd. (NASDAQ:ROIV) Suggests It's 22% Undervalued
Aug 12Roivant Sciences Ltd. (NASDAQ:ROIV) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Jun 30Shareholder Returns
ROIV | US Biotechs | US Market | |
---|---|---|---|
7D | -0.09% | 2.0% | -0.3% |
1Y | 19.7% | 12.4% | 22.3% |
Return vs Industry: ROIV exceeded the US Biotechs industry which returned 12% over the past year.
Return vs Market: ROIV underperformed the US Market which returned 24.2% over the past year.
Price Volatility
ROIV volatility | |
---|---|
ROIV Average Weekly Movement | 4.6% |
Biotechs Industry Average Movement | 10.5% |
Market Average Movement | 5.7% |
10% most volatile stocks in US Market | 15.4% |
10% least volatile stocks in US Market | 2.9% |
Stable Share Price: ROIV has not had significant price volatility in the past 3 months.
Volatility Over Time: ROIV's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2014 | 908 | Matt Gline | roivant.com |
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases.
Roivant Sciences Ltd. Fundamentals Summary
ROIV fundamental statistics | |
---|---|
Market cap | US$8.06b |
Earnings (TTM) | US$4.35b |
Revenue (TTM) | US$124.80m |
1.8x
P/E Ratio64.1x
P/S RatioIs ROIV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ROIV income statement (TTM) | |
---|---|
Revenue | US$124.80m |
Cost of Revenue | US$517.30m |
Gross Profit | -US$392.50m |
Other Expenses | -US$4.74b |
Earnings | US$4.35b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 5.89 |
Gross Margin | -314.52% |
Net Profit Margin | 3,484.86% |
Debt/Equity Ratio | 6.9% |
How did ROIV perform over the long term?
See historical performance and comparison